Shopping Cart

Remove All

Your shopping cart is currently empty

Proceed to checkout Continue shopping

Pelitrexol

Name: Pelitrexol
Brand: TargetMol
SKU: T14147
Rating: 4.5 (1 reviews)

Copy Product Info

😃Good

Catalog No. T14147Cas No. 446022-33-9

Alias AG2037, AG 2037

Pelitrexol (AG2037) is a GARFT inhibitor, which can inhibit the activity of mTORC1, reduce intracellular guanine nucleotides and block the cell cycle in the s-phase, with antiproliferative activity, and can be used in non-small cell lung cancer.

Pelitrexol

Copy Product Info

😃Good

Purity: 98.03%

Catalog No. T14147Alias AG2037, AG 2037Cas No. 446022-33-9

Pack Size	Price	USA Warehouse	Global Warehouse
5 mg	$521	8-10 weeks	8-10 weeks
25 mg	$1,530	8-10 weeks	8-10 weeks
50 mg	$1,990	8-10 weeks	8-10 weeks
100 mg	$3,310	8-10 weeks	8-10 weeks
1 mL x 10 mM (in DMSO)	$631	8-10 weeks	8-10 weeks

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:98.03%

Appearance:Solid

Color:White

Resource Download

COA

Product Introduction

Bioactivity

Description	Pelitrexol (AG2037) is a GARFT inhibitor, which can inhibit the activity of mTORC1, reduce intracellular guanine nucleotides and block the cell cycle in the s-phase, with antiproliferative activity, and can be used in non-small cell lung cancer.
Targets&IC50	mTORC1:27-40 nM
In vitro	Pelitrexol potently inhibits mTORC1 signaling (IC₅₀ ≈ 27-40 nM) in NSCLC cells, causes G1 arrest, and acts via GARFT inhibition. The effects of Pelitrexol are reversed by hypoxanthine, confirming target specificity[1].
In vivo	In a mouse xenograft model of non-small-cell lung cancer (NSCLC), intraperitoneal administration of Pelitrexol at 10 mg/kg or 20 mg/kg every 4 days for 3 weeks reduced tumor growth by 64% and 69%, respectively. At 20 mg/kg, it also suppressed mTORC1-dependent phosphorylation of S6K1, S6RP, and CAD, confirming disruption of purine biosynthesis via GARFT inhibition[1].
Synonyms	AG2037, AG 2037

Chemical Properties

Molecular Weight	463.51
Formula	C₂₀H₂₅N₅O₆S
Cas No.	446022-33-9
Smiles	O=C1C2=C(NC[C@@H](CCC=3SC(C(N[C@@H](CCC(O)=O)C(O)=O)=O)=CC3C)C2)NC(N)=N1
Relative Density.	1.64g/cm3

Storage & Solubility Information

Storage

store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 20 mg/mL (43.15 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (4.31 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.1575 mL	10.7873 mL	21.5745 mL	107.8725 mL
5 mM	0.4315 mL	2.1575 mL	4.3149 mL	21.5745 mL
10 mM	0.2157 mL	1.0787 mL	2.1575 mL	10.7873 mL
20 mM	0.1079 mL	0.5394 mL	1.0787 mL	5.3936 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc